Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Virus or bacteriophage
Reexamination Certificate
2000-06-15
2002-09-24
McKelvey, Terry (Department: 1636)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Virus or bacteriophage
C424S215100, C514S04400A
Reexamination Certificate
active
06455038
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention pertains to methods for treating ras-mediated proliferative disorders in a mammal using reovirus.
2. References
The following publications, patent applications and patents are cited in this application:
U.S. Pat. No. 5,023,252
Armstrong, G. D. et al. (1984),
Virology
138:37;
Aronheim, A., et al.,(1994)
Cell
, 78:949-961
Barbacid, M.,
Annu. Rev. Biochem
., 56:779-827 (1987);
Berrozpe, G., et al. (1994),
Int. J. Cancer
, 58:185-191
Bischoff, J. R. and Samuel, C. E., (1989)
Virology
, 172:106-115
Cahill, M. A., et al.,
Curr. Biol
., 6:16-19 (1996);
Chandron and Nibert, “Protease cleavage of reovirus capsid protein mu1 and mu1C is blocked by alkyl sulfate detergents, yielding a new type of infectious subvirion particle”,
J. of Virology
72(1):467-75 (1998
Chaubert, P. et al. (1994),
Am. J. Path
. 144:767
; Bos, J
. (1989)
Cancer Res
. 49:4682
Cuff et al., “Enteric reovirus infection as a probe to study immunotoxicity of the gastrointestinal tract”
Toxicological Sciences
42(2):99-108 (1998)
Der, S. D. et al.,
Proc. Natl. Acad. Sci. USA
94:3279-3283 (1997)
Dudley, D. T. et al.,
Proc. Natl. Acad. Sci. USA
92:7686-7689 (1995)
Duncan et al., “Conformational and functional analysis of the C-terminal globular head of the reovirus cell attachment protein”
Virology
182(2):810-9 (1991)
Fields, B. N. et al. (1996),
Fundamental Virology
, 3rd Edition, Lippincott-Raven;
Gentsch, J. R. K. and Pacitti, A. F. (1985),
J. Virol
. 56:356;
E. Harlow and D. Lane, “Antibodies: A laboratory manual”, Cold Spring Harbor Laboratory (1988)
Helbing, C. C. et al.,
Cancer Res
. 57:1255-1258 (1997)
Hu, Y. and Conway, T. W. (1993),
J. Interferon Res
., 13:323-328
Laemmli, U. K., (1970)
Nature
, 227:680-685
Lee. J. M. et al. (1993)
PNAS
90:5742-5746;
Lee, P. W. K. et al. (1981)
Virology
, 108:134-146
Levitzki, A. (1994)
Eur. J. Biochem
. 226: 1; James, P. W., et al. (1994)
Oncogene
9:3601
; Bos, J
. (1989)
Cancer Res
. 49:4682
Lowe, S. W. et al. (1994)
Science
, 266:807-810;
Lyon, H.,
Cell Biology, A Laboratory Handbook
, J. E. Celis, ed., Academic Press, 1994, p. 232
Mah et al., “The N-terminal quarter of reovirus cell attachment protein sigma 1 possesses intrinsic virion-anchoring function”
Virology
179(1):95-103 (1990)
McRae, M. A. and Joklik, W. K., (1978)
Virology
, 89:578-593
Millis, NE et al. (1995)
Cancer Res
. 55:1444;
Mundschau, L. J. and Faller, D. V., (1992)
J. Biol. Chem
., 267:23092-23098
Nagata, L., et al. ,(1984)
Nucleic Acids Res
., 12:8699-8710
Paul R. W. et al. (1989)
Virology
172:382-385
Raybaud-Diogene, H. et al. (1997)
J. Clin. Oncology
, 15(3):1030-1038;
Remington's Pharmaceutical Sciences
, Mace Publishing Company, Philadelphia Pa. 17
th
ed. (1985)
Robinson, M. J. and Cobb, M. H.,
Curr. Opin. Cell. Biol
. 9:180-186 (1997);
Rosen, L. (1960)
Am. J. Hyg
. 71:242;
Sabin, A. B. (1959),
Science
130:966
Samuel, C. E. and Brody, M., (1990)
Virology
, 176:106-113;
Smith, R. E. et al., (1969)
Virology
, 39:791-800
Stanley, N. F. (1967)
Br. Med. Bull
. 23:150
Strong, J. E. et al.,(1993)
Virology
, 197:405-411;
Strong, J. E. and Lee, P. W. K., (1996)
J. Virol
., 70:612-616
Trimble, W. S. et al. (1986)
Nature
, 321:782-784
Turner and Duncan, “Site directed mutagenesis of the C-terminal portion of reovirus protein sigma1:evidence for a conformation-dependent receptor binding domain”
Virology
186(1):219-27 (1992);
Waters, S. D. et al.,
J. Biol. Chem
. 270:20883-20886 (1995)
Wiessmuller, L. and Wittinghofer, F. (1994),
Cellular Signaling
6(3):247-267;
Wong, H., et al., (1994)
Anal. Biochem
., 223:251-258
Yang, Y. L. et al.
EMBO J
. 14:6095-6106 (1995)
Yu, D. et al. (1996)
Oncogene
13:1359.
All of the above publications, patent applications and patents are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent application or patent was specifically and individually indicated to be incorporated by reference in its entirety.
State of the Art
Normal cell proliferation is regulated by a balance between growth-promoting proto-oncogenes and growth-constraining tumor-suppressor genes. Tumorigenesis can be caused by genetic alterations to the genome that result in the mutation of those cellular elements that govern the interpretation of cellular signals, such as potentiation of proto-oncogene activity or inactivation of tumor suppression. It is believed that the interpretation of these signals ultimately influences the growth and differentiation of a cell, and that misinterpretation of these signals can result in neoplastic growth (neoplasia).
Genetic alteration of the proto-oncogene Ras is believed to contribute to approximately 30% of all human tumors (Wiessmuller, L. and Wittinghofer, F. (1994),
Cellular Signaling
6(3):247-267; Barbacid, M. (1987)
A Rev. Biochem
. 56, 779-827). The role that Ras plays in the pathogenesis of human tumors is specific to the type of tumor. Activating mutations in Ras itself are found in most types of human malignancies, and are highly represented in pancreatic cancer (80%), sporadic colorectal carcinomas (40-50%), human lung adenocarcinomas (15-24%), thyroid tumors (50%) and myeloid leukemia (30%) (Millis, N E et al. (1995)
Cancer Res
. 55:1444; Chaubert, P. et al. (1 994),
Am. J. Path
. 144:767; Bos, J. (1989)
Cancer Res
. 49:4682). Ras activation is also demonstrated by upstream mitogenic signaling elements, notably by tyrosine receptor kinases (RTKs). These upstream elements, if amplified or overexpressed, ultimately result in elevated Ras activity by the signal transduction activity of Ras. Examples of this include overexpression of PDGFR in certain forms of glioblastomas, as well as in c-erbB-2
eu in breast cancer (Levitzki, A. (1994)
Eur. J. Biochem
. 226:1; James, P. W., et al. (1994)
Oncogene
9:3601; Bos, J. (1989)
Cancer Res
. 49:4682).
Current methods of treatment for neoplasia include surgery, chemotherapy and radiation. Surgery is typically used as the primary treatment for early stages of cancer; however, many tumors cannot be completely removed by surgical means. In addition, metastatic growth of neoplasms may prevent complete cure of cancer by surgery. Chemotherapy involves administration of compounds having antitumor activity, such as alkylating agents, antimetabolites, and antitumor antibiotics. The efficacy of chemotherapy is often limited by severe side effects, including nausea and vomiting, bone marrow depression, renal damage, and central nervous system depression. Radiation therapy relies on the greater ability of normal cells, in contrast with neoplastic cells, to repair themselves after treatment with radiation. Radiotherapy cannot be used to treat many neoplasms, however, because of the sensitivity of tissue surrounding the tumor. In addition, certain tumors have demonstrated resistance to radiotherapy and such may be dependent on oncogene or anti-oncogene status of the cell (Lee. J. M. et al. (1993)
PNAS
90:5742-5746; Lowe. S. W. et al. (1994)
Science
, 266:807-810; Raybaud-Diogene. H. et al. (1997)
J. Clin. Oncology
, 15(3):1030-1038). In view of the drawbacks associated with the current means for treating neoplastic growth, the need still exists for improved methods for the treatment of most types of cancers.
SUMMARY OF THE INVENTION
The present invention pertains to a method of treating a ras-mediated proliferative disorder in a mammal selected from dogs, cats, sheep, goats, cattle, horses, pigs, humans and non-human primates, comprising administering to the proliferating cells an effective amount of one or more reoviruses in the absence of BCNU under conditions which result in substantial lysis of the proliferating cells. The reovirus may be a mammalian reovirus or an avian reovirus. The reovirus may be modified such that the outer capsid is removed, the virion is packaged in a liposome or micelle or the proteins of the outer capsid have been mutated. The reovirus can be administered in a single dose or in multiple doses. The proliferative
Coffey Matthew C.
Lee Patrick W. K.
Strong James
Burns Doane , Swecker, Mathis LLP
McKelvey Terry
Oncolytics Biotech Inc.
LandOfFree
Reovirus for the treatment of cellular proliferative disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Reovirus for the treatment of cellular proliferative disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reovirus for the treatment of cellular proliferative disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2890180